Philogen SpA (PHIL) AI Stock Analysis

• Market Cap: €719.37M
• Dividend Yield: N/A
• Average Volume (3M): 19.28K
• Price to Earnings (P/E): 21.6
• Beta (1Y): -0.09
• Revenue Growth: 3346.54%
• EPS Growth: N/A
• Country: IT
• Employees: 174
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.37
• Shares Outstanding: 29,242,860
• 10 Day Avg. Volume: 19,753
• 30 Day Avg. Volume: 19,281
• PEG Ratio: -0.02
• Price to Book (P/B): 5.67
• Price to Sales (P/S): 10.62
• P/FCF Ratio: 20.32
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €25.00
• Price Target Upside: 5.04% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 70 Outperform
• Price Target: €26.00 ▲(9.24% Upside)

Philogen SpA's overall stock score is driven by strong financial performance and positive technical indicators. The company's transition to profitability and solid balance sheet are significant strengths. The technical analysis supports a positive trend, although valuation suggests moderate growth potential. The absence of earnings call and corporate events data does not impact the score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates expanding market reach and effective product adoption, supporting long-term business sustainability.

Profitability

High profit margins reflect strong pricing power and cost management, enhancing the company's ability to reinvest in growth and innovation.

Balance Sheet Health

A strong balance sheet with low leverage provides financial stability and flexibility, enabling strategic investments and resilience against economic downturns.

Negative Factors

Free Cash Flow Growth

Negative free cash flow growth may limit the company's ability to fund new projects and return value to shareholders, potentially impacting long-term growth.

EBITDA Margin Fluctuations

Fluctuating EBITDA margins can indicate volatility in operating efficiency, which may affect predictability of earnings and long-term profitability.

Cash Flow Management

While cash flow management has improved, challenges in free cash flow growth could constrain the company's ability to invest in growth opportunities.

Philogen SpA Business Overview & Revenue Model

Company Description

Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases. It is developing Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF developed intralesional treatment for locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory product consisting of the human L19 antibody fused to the human cytokine interleukin-2 (IL2), which is in phase II clinical trial for the treatment of non-small cell lung cancer. The company is also developing Dodekin, a human immunostimulatory product that comprises vascular targeting antibody fused to interleukin-12 that is in phase I/II clinical trial to treat advanced solid tumors; Dekavil (F8IL10), an anti-inflammatory product, which is in phase I clinical trial for the treatment of chronic inflammation; Onco IX (PHC-102), a 99mTc labelled small molecule radiotracer for the non-invasive detection of carbonic anhydrase IX (CAIX) expressing solid tumors that is in phase 1 clinical trial; and OncoFAP, a small molecule radiotracer for the non-invasive detection of various metastatic solid tumors targeting fibroblast activation protein, which is in phase 1 clinical trial. Philogen S.p.A. was founded in 1996 and is based in Sovicille, Italy.

How the Company Makes Money

Philogen generates revenue primarily through strategic partnerships and collaborations with pharmaceutical companies, which provide funding for research and development initiatives in exchange for rights to develop and commercialize its therapeutic products. The company may also earn revenue from milestone payments and royalties based on the sales of products that emerge from these partnerships. Additionally, Philogen may receive grants or funding from public and private institutions that support innovative biopharmaceutical research. Its business model is centered around leveraging its proprietary technologies and extensive expertise in the field to create value through successful drug development and commercialization.

Philogen SpA Financial Statement Overview

Summary

Philogen SpA has demonstrated significant financial improvement, transitioning from losses to profitability. The income statement shows strong revenue and profit growth, while the balance sheet reflects low leverage and high return on equity. Cash flow management has improved, although free cash flow growth remains a challenge. The company is on a positive trajectory, with strong financial health and growth potential.

Income Statement

Philogen SpA has shown a strong improvement in its income statement over the years, particularly in the TTM period. The company has achieved a positive net profit margin of 54.11% and a gross profit margin of 51.57% in the TTM, indicating robust profitability. Revenue growth rate has been positive, with a 4.43% increase in the TTM. However, the EBIT and EBITDA margins have seen some fluctuations, with the TTM EBIT margin at 46.15% and EBITDA margin at 51.50%. The company has successfully transitioned from losses in earlier years to profitability, showcasing a strong upward trajectory.

Balance Sheet

Philogen SpA's balance sheet is solid, with a low debt-to-equity ratio of 0.09 in the TTM, indicating low leverage and financial stability. The return on equity is impressive at 34.72%, reflecting efficient use of equity to generate profits. The equity ratio is healthy, suggesting a strong capital structure. The company has maintained a stable balance sheet with consistent improvements in equity and asset management over the years.

Cash Flow

The cash flow statement shows a mixed performance. While the operating cash flow to net income ratio is strong at 1.91 in the TTM, indicating good cash generation relative to net income, the free cash flow growth rate has been negative at -2.02%. The free cash flow to net income ratio is high at 0.94, suggesting efficient cash conversion. Despite some fluctuations in free cash flow growth, the company has improved its cash flow management significantly compared to previous years.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	84.86M	74.00M	23.13M	23.71M	2.50M	4.78M
Gross Profit	43.76M	54.42M	5.67M	10.53M	-8.14M	-5.05M
EBITDA	43.70M	44.75M	-2.05M	-1.17M	-12.98M	-10.53M
Net Income	45.91M	45.29M	-6.16M	-5.38M	-15.72M	-13.29M
Balance Sheet
Total Assets	159.35M	168.45M	119.27M	125.83M	132.75M	85.47M
Cash, Cash Equivalents and Short-Term Investments	100.02M	113.73M	75.34M	86.20M	101.68M	61.94M
Total Debt	11.50M	11.51M	14.91M	15.76M	16.49M	17.70M
Total Liabilities	33.54M	29.80M	28.68M	27.91M	27.67M	29.80M
Stockholders Equity	125.81M	138.66M	90.59M	97.92M	105.09M	55.67M
Cash Flow
Free Cash Flow	37.15M	38.67M	-10.37M	-9.15M	-25.85M	-16.81M
Operating Cash Flow	39.55M	40.84M	-4.82M	-4.94M	-19.03M	-13.16M
Investing Cash Flow	-36.03M	-22.28M	159.00K	24.20M	-47.77M	17.77M
Financing Cash Flow	-4.80M	-3.78M	-4.17M	-3.78M	63.05M	3.79M

Philogen SpA Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 23.80
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:PHIL, the sentiment is Neutral. The current price of 23.8 is below the 20-day moving average (MA) of 23.92, above the 50-day MA of 23.49, and above the 200-day MA of 21.82, indicating a neutral trend. The MACD of 0.24 indicates Positive momentum. The RSI at 48.88 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IT:PHIL.

Philogen SpA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PHN	71 Outperform	€425.48M	24.98	―	2.25%	13.75%	16.66%
PHIL	70 Outperform	€719.37M	21.63	45.54%	―	3346.54%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Philogen SpA Corporate Events

Philogen S.p.A. Updates Share Buyback Program

Philogen S.p.A. has announced an update on its share buyback program, purchasing 902 shares between October 6 and October 10, 2025, at an average price of Euro 22.90 per share, totaling Euro 20,655.80. Since the program’s inception, Philogen has acquired 31,947 shares, representing 0.0787% of its share capital, with a total value of Euro 713,994.62. This strategic move is part of Philogen’s efforts to manage its capital structure and potentially enhance shareholder value.

The most recent analyst rating on (IT:PHIL) stock is a Hold with a EUR24.50 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.

Philogen S.p.A. Updates on Share Buyback Program

Philogen S.p.A. announced an update on its share buyback program, revealing the purchase of 50 shares between September 29 and October 3, 2025, at an average price of Euro 22.90 per share, totaling Euro 1,145.00. Since the program’s inception, the company has acquired 31,045 shares, representing 0.0764% of its share capital, amounting to Euro 693,338.82. This strategic move is part of Philogen’s broader efforts to manage its capital structure, potentially enhancing shareholder value and reinforcing its market position in the biotechnology sector.

The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR25.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.

Philogen Updates on Share Buyback Program

Philogen S.p.A. announced an update on its share buyback program, revealing the purchase of 1,547 shares from September 22 to 26, 2025, at an average price of €22.5250 per share, totaling €34,846.10. Since the program’s inception, Philogen has acquired 30,995 shares, representing 0.0763% of its share capital, with a total value of €692,193.82. This buyback initiative reflects Philogen’s strategic financial management and could potentially enhance shareholder value by reducing the number of outstanding shares.

The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR25.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.

Philogen Reports Strong Revenue Growth and Advances in Clinical Pipeline

Philogen S.p.A. reported its half-year financial results for 2025, showing a significant increase in revenue from contracts with customers, driven by a new contract with RayzeBio. Despite a negative net result, the company’s financial position remains strong, supported by liquidity and expected milestones from license agreements. The company is progressing with its regulatory submissions for Nidlegy™ and advancing clinical trials for various cancer treatments, indicating a robust pipeline and long-term sustainability.

The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR25.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.

Philogen S.p.A. Updates on Share Buyback Program

Philogen S.p.A. has announced an update on its share buyback program, revealing the purchase of 2,000 shares, equating to 0.0049% of its share capital, at an average price of Euro 22.4727 per share. This move is part of a broader strategy to enhance shareholder value, with the company having acquired a total of 29,448 shares since the program’s inception. The buyback reflects Philogen’s confidence in its market position and commitment to its stakeholders, potentially impacting its financial standing and investor perception.

The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR26.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.

Philogen Finalizes $1.35 Billion OncoACP3 License Agreement with RayzeBio

Philogen S.p.A. announced that its subsidiary, Philochem AG, has finalized a license agreement with RayzeBio, a Bristol-Myers Squibb subsidiary, for the therapeutic and diagnostic agent OncoACP3, aimed at treating prostate cancer. The agreement, effective following U.S. antitrust approval, includes an initial payment of $350 million to Philochem, with potential milestone payments up to $1 billion and royalties. This partnership is expected to enhance Philogen’s position in the biotechnology sector and advance RayzeBio’s leadership in radiopharmaceuticals, potentially revolutionizing prostate cancer treatment.

The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR33.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.